---
title: "Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289928583.md"
description: "Acceptance of abstracts highlights Nexalin's innovative DIFS™ treatment platform, delivering 15 mA at 77.5 Hz. Clinical studies demonstrate significant enhancements in anxiety, depression, insomnia, and overall quality of life."
datetime: "2026-06-16T13:17:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289928583.md)
  - [en](https://longbridge.com/en/news/289928583.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289928583.md)
---

# Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Acceptance of abstracts highlights Nexalin's innovative DIFS™ treatment platform, delivering 15 mA at 77.5 Hz. Clinical studies demonstrate significant enhancements in anxiety, depression, insomnia, and overall quality of life.

### Related Stocks

- [NXL.US](https://longbridge.com/en/quote/NXL.US.md)
- [NXLIW.US](https://longbridge.com/en/quote/NXLIW.US.md)

## Related News & Research

- [EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life](https://longbridge.com/en/news/289332930.md)
- [Nexalin Q2 FY26 net loss widens 42% to $2.24 million; revenue drops 83% to $12,161](https://longbridge.com/en/news/295711050.md)
- [Silo Pharma says Canada issues notice of allowance for SPC-15 PTSD patent application](https://longbridge.com/en/news/296265804.md)
- [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)